Inhibikase Therapeutics, Inc. Common Stock
Veridion Score
Composite trend over time
Why is IKT moving today?
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
Warehouse intelligence for IKT.
IKT insider activity
Inhibikase Therapeutics, Inc. Common Stock
No multi-insider buying cluster in the last 90 days
Net buying: $3.0M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2025-11-24 | 2025-11-21 | Sands Capital Alternatives, LLC | Insider | buy | $1.45 | 2,068,965 | 13,018,965 | $3.0M | SEC Form 4 |
IKT contract awards, year to date.
Public federal awards linked to this ticker.
IKT lobbying filings, year to date.
Registered lobbying filings matched to Inhibikase Therapeutics, Inc. Common Stock.